Which FDA center typically takes the lead in reviewing drug delivery combination products?

The FDA's Center for Drug Evaluation and Research (CDER) often takes the lead in reviewing drug delivery combination products, especially when the primary mode of action is attributable to the drug. However, the Center for Devices and Radiological Health (CDRH) provides crucial consultation on the device aspects.

Are there specific human factors considerations for drug delivery devices?

Yes, human factors engineering is particularly critical for drug delivery devices due to the need for safe and effective use by patients, often in a home setting. This includes ensuring proper design for ease of use, clear instructions, and mitigation of potential use errors, as outlined in FDA guidance documents on human factors for medical devices.

All terms

Market SegmentsStrategic Landscape

Drug Delivery Devices

Devices that administer therapeutics - autoinjectors, pumps, inhalers.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Drug delivery devices include prefilled syringes, autoinjectors (e.g., GLP-1 pens), wearable injectors (West, Insulet), implantable pumps, and inhalation devices. Often regulated as combination products via CDER-led review with CDRH consult. Products include infusion pumps, autoinjectors, inhalers and wearable injectors. Many are combination products, where FDA assigns a lead center based on primary mode of action. Human factors testing is critical because use errors can harm patients.

What the regulation says

Drug delivery devices, when combined with a drug, are typically regulated as combination products by health authorities like the FDA. The FDA outlines requirements for combination products in 21 CFR Part 3, and often involves a lead center, such as the Center for Drug Evaluation and Research (CDER) with consultation from the Center for Devices and Radiological Health (CDRH), to ensure both the drug and device aspects meet applicable regulations. The EU MDR (Regulation (EU) 2017/745) also addresses devices incorporating a medicinal substance, requiring consultation with a medicines authority on the safety, quality, and usefulness of the substance.

What this means in practice

GLP-1 demand has driven massive autoinjector and prefilled-syringe capacity expansion. Combination product CMC and human factors are gating items.

Examples

A pre-filled syringe containing a vaccine is a drug delivery device regulated as a combination product, with the syringe being the device component and the vaccine being the drug component.
An autoinjector designed to deliver epinephrine in an emergency is a combination product; the device facilitates rapid drug administration, and the drug provides the therapeutic effect.
An insulin pump, when pre-filled with insulin, functions as a drug delivery device and is regulated as a combination product due to the integrated drug and device components.

Common pitfalls

•Assuming that drug delivery devices are solely regulated as medical devices overlooks the critical aspect of combination product regulation.
•Neglecting to consider the human factors engineering requirements specific to drug delivery devices can lead to usability issues and regulatory non-compliance.
•Failing to adequately address the Chemistry, Manufacturing, and Controls (CMC) aspects for the drug component of a combination product can cause significant regulatory delays.
•Overlooking post-market surveillance requirements that apply to both the device and drug components of a combination product can result in regulatory sanctions.

Frequently asked questions

A combination product in this context is a product comprised of two or more regulated components, such as a drug and a device, that are combined to achieve a specific therapeutic effect. For drug delivery devices, this typically means the device is pre-filled or co-packaged with a drug.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

Combination Product

Product comprised of two or more regulated components - e.g., drug-device, biologic-device.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FDA·1MedTech Dive·1AdvaMed·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Devices that administer therapeutics - autoinjectors, pumps, inhalers.

·GLP-1 demand has driven massive autoinjector and prefilled-syringe capacity expansion.
·Combination product CMC and human factors are gating items.
·Often regulated as combination products via CDER-led review with CDRH consult.

Remember this

Watch out: Assuming that drug delivery devices are solely regulated as medical devices overlooks the critical aspect of combination product regulation.

Related terms

Combination Product

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms